Allergan Aesthetics, an AbbVie company, announces that it has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago.
Following the completion of a clinical trial to be initiated in 2021, Allergan Aesthetics will have the right to exercise an option to acquire Cypris Medical, including the company’s Xact device. The planned clinical trial will evaluate the safety and effectiveness of Xact in treating midface descent as well as for neck lifts.
Replacing the scalpel, Xact is designed to allow for lifting and suturing of the superficial muscular aponeurotic system (SMAS), the same tissue mobilized in a facelift, but in a minimally-invasive manner. The innovative technology intends to provide patients surgery-like results in the office with little to no downtime.
“As a global leader in aesthetics, we are proud to support the research of an innovative device that complements our iconic portfolio of non-invasive treatment options like Botox Cosmetic and our Juvéderm Collection of Fillers. We know there is continued unmet need for minimally-invasive procedures for midface descent, and Xact affords us the ability to create a new alternative for our customers so they can continue to offer leading-edge treatments to patients.”
— Carrie Strom, SVP AbbVie and President, Global Allergan Aesthetics
“As the market leader in facial aesthetics, Allergan Aesthetics is the ideal partner to lead the advancement and continued development of Xact. We share the same vision with respect to product safety, efficacy and data-driven innovation which allow us to offer plastic surgeons and patients new options for aesthetic medicine.”
— Dan Holton, President and CEO, Cypris Medical
[AbbVie, PR Newswire]
Related Content:
Allergan Aesthetics Acquires Luminera
FDA Approves the Chin Filler JUVÉDERM VOLUMA XC from Allergan Aesthetics
AbbVie Creates Allergan Aesthetics and Names New Leadership Team
